Meeting Abstract
BibTex RIS Cite

NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES

Year 2022, Volume: 5 Issue: S-1, 45 - 45, 09.08.2022
https://doi.org/10.26650/JARHS2021-1142702

Abstract

Objectives: Oral squamous cell carcinoma (OSCC) has a high morbidity and mortality rates, but there are no reliable biomarkers to define patients in early
phases of disease. In our study (TUBITAK-SBAG-114S497), we aimed to investigate the potential epigenetic biomarker candidate genes observed
methylation-dependent expression loss via methylation and expression array methods in OSCC patients.
Material and Methods: Methylation and expression profiling in tumor and conjugate-normal tissue samples of 6 OSCC patients were analyzed by
“IlluminaHumanMethylation450 chips” and “Illumina iScan”, respectively. Methylation/expression array data were analyzed and interpreted by R(v3.5.1)
environment using ChAMP and limma/lumi packages, and then the significant decreased expression changes due to hypermethylation of the candidate
gene was detected. The selected candidate gene was validated in tumor and matched-normal tissues and body fluids (serum and saliva) of 20 OSCC
patients by QRT-PCR/QMSP methods.
Results: According to the array results, it was determined that the expression levels of the candidate gene were decreased due to methylation
(DiffScore:13.18826; FoldChange:-1.08345). This candidate gene (unpublished data), which plays an important role in ubiquitin-ligase activity, was found
to be methylated in 45% tumor, 40% matched-normal tissue, 10% serum and 30% saliva samples. 50% of the patients observed methylation in the tumor
tissue showed the differentially decreased expression levels.
Conclusion: It is thought that this candidate gene, whose expression level decreased due to methylation, will be a candidate epigenetic biomarker for the
early diagnosis of the subtypes of OSCC. Further validation of this candidate gene will be needed in the larger OSCC cohorts.

Supporting Institution

TUBITAK

Project Number

TUBITAK-SBAG-114S497

References

  • Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605-44.

NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES

Year 2022, Volume: 5 Issue: S-1, 45 - 45, 09.08.2022
https://doi.org/10.26650/JARHS2021-1142702

Abstract

Objectives: Oral squamous cell carcinoma (OSCC) has a high morbidity and mortality rates, but there are no reliable biomarkers to define patients in early
phases of disease. In our study (TUBITAK-SBAG-114S497), we aimed to investigate the potential epigenetic biomarker candidate genes observed
methylation-dependent expression loss via methylation and expression array methods in OSCC patients.
Material and Methods: Methylation and expression profiling in tumor and conjugate-normal tissue samples of 6 OSCC patients were analyzed by
“IlluminaHumanMethylation450 chips” and “Illumina iScan”, respectively. Methylation/expression array data were analyzed and interpreted by R(v3.5.1)
environment using ChAMP and limma/lumi packages, and then the significant decreased expression changes due to hypermethylation of the candidate
gene was detected. The selected candidate gene was validated in tumor and matched-normal tissues and body fluids (serum and saliva) of 20 OSCC
patients by QRT-PCR/QMSP methods.
Results: According to the array results, it was determined that the expression levels of the candidate gene were decreased due to methylation
(DiffScore:13.18826; FoldChange:-1.08345). This candidate gene (unpublished data), which plays an important role in ubiquitin-ligase activity, was found
to be methylated in 45% tumor, 40% matched-normal tissue, 10% serum and 30% saliva samples. 50% of the patients observed methylation in the tumor
tissue showed the differentially decreased expression levels.
Conclusion: It is thought that this candidate gene, whose expression level decreased due to methylation, will be a candidate epigenetic biomarker for the
early diagnosis of the subtypes of OSCC. Further validation of this candidate gene will be needed in the larger OSCC cohorts.

Project Number

TUBITAK-SBAG-114S497

References

  • Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605-44.
There are 1 citations in total.

Details

Primary Language English
Subjects Clinical Sciences
Journal Section Meeting Abstract
Authors

Semra Demokan 0000-0002-8066-8419

Sena Sen 0000-0003-3967-8903

Onder Eryılmaz 0000-0001-5717-0244

Sevde Comert 0000-0001-8544-955X

Murat Ulusan 0000-0003-3885-1620

Mehmet Nejat Dalay 0000-0003-1479-3577

Project Number TUBITAK-SBAG-114S497
Publication Date August 9, 2022
Submission Date July 18, 2022
Published in Issue Year 2022 Volume: 5 Issue: S-1

Cite

MLA Demokan, Semra et al. “NOVEL EPIGENETIC BIOMARKER DETERMINATION FOR OSCC BY ARRAY-BASED EPIGENOMIC AND TRANSCRIPTOMIC TECHNIQUES”. Sağlık Bilimlerinde İleri Araştırmalar Dergisi, vol. 5, no. S-1, 2022, pp. 45-45, doi:10.26650/JARHS2021-1142702.